Evicenter
MarkdownMedical informationP&T meetings
Cretostimogene grenadenorepvec (CG0070)

BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Manufacturer
CG Oncology
Launch
Not announced
Last updated
161 sources

Section 3 of 6

Product information and disease description

273 evidence topics · 114 sources

Product description

Phase of product development

Launch

No evidence found.

Product information

Generic, brand name and therapeutic class of product
Development code and registry intervention names
Registry fieldQuoted record
Intervention name“Cretostimogene Grenadenorepvec”
Other name“CG0070”
Intervention description“Engineered Oncolytic Adenovirus”
Co-administered agent“n-dodecyl-B-D-maltoside”
Co-administered agent description“Transduction-enhancing agent”
Brand name

No evidence found.

Dosage forms and strengths
Commercial vial strength, fill volume, and storage conditions

No evidence found.

Average sales price and wholesale acquisition cost

Not applicable.

American hospital formulary service (AHFS), or other drug classification
AHFS classification

No evidence found.

Indication
Pharmacology
Mechanism of action
Pharmacodynamics
Pharmacokinetics
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions

Not applicable.

Special populations
Use in pregnancy and lactation, in children, and in renal or hepatic impairment

No evidence found.

Drug/Drug, drug/disease interactions
Effects of other drugs on Cretostimogene grenadenorepvec
Effects of Cretostimogene grenadenorepvec on other drugs

No evidence found.

Dosing and administration
Dosage
Dose modification

No evidence found.

Administration
Access and distribution
Co-prescribed/Concomitant therapies
Dwell times of the pretreatment agent and cretostimogene
Effect of Cretostimogene grenadenorepvec on quality measures
Product-specific effect on quality measures

No evidence found.

Product comparison
Guideline table of bladder-sparing options for carcinoma in situ with or without papillary disease
CompoundStudy designnFollow-up (months)CR at 3 months (%)CR at 6 months (%)CR at 12 months (%)Adverse events
Nadofaragene firadenovec“Phase III Cis Cohort”“103”“19.7”“53.4”“40.8”“24.3”“G3 4%”
Cretostimogene grenadenorepvec (CG0070)“Phase II”“45”Not reportedNot reported“58 CIS”; “50 CIS+P”Not reported“G1-2 82.5% G ≥ 3 4.5%”
Nogapendekin alfa inbakicept plus BCG“Phase II/III QUILT 3032 CA”“82”“23.9”“55.0”“56.0”“45.0”“G1-2 86% G ≥ 3 23%”
TAR-200“Phase II b SunRISe-1 C2”“81”“20.2”“78.8”“58.8”“45.9”“Any G 83.5% G ≥ 3 12.9%”
Pembrolizumab“Phase II Cohort A KEYNOTE-057”“96”“36.4”“41.0”Not reported“18.7”“G1-2 53.0% G ≥ 3 13%”
Nadofaragene firadenovec: indication, dosing, and efficacy in prescribing information

Place of product in therapy

Disease description

Definition and etiology
Definition of BCG-unresponsive disease: FDA guidance

“For the purposes of this guidance, BCG-unresponsive disease is defined as being at least one of” (opens the source at this quote in a new tab)

“Persistent or recurrent Carcinoma in Situ (CIS) alone or with recurrent” (opens the source at this quote in a new tab)

“(noninvasive papillary disease/tumor invades the subepithelial connective tissue) disease” (opens the source at this quote in a new tab)

“within 12 months of completion of adequate BCG therapy” (opens the source at this quote in a new tab)

“disease within 6 months of completion of adequate BCG” (opens the source at this quote in a new tab)

“T1 high-grade disease at the first evaluation following an induction BCG” (opens the source at this quote in a new tab)

“At least five of six doses of an initial induction course plus at least two of three doses of” (opens the source at this quote in a new tab)

“At least five of six doses of an initial induction course plus at least two of six doses of a” (opens the source at this quote in a new tab)

“Patients with BCG-unresponsive NMIBC are unlikely to benefit from further therapy with BCG” (opens the source at this quote in a new tab)

“Patients with BCG-unresponsive NMIBC include those who experienced recurrence with either” (opens the source at this quote in a new tab)

“papillary disease or CIS or both and who have completely resected disease, resected disease with” (opens the source at this quote in a new tab)

“CIS, or CIS alone at trial entry.” (opens the source at this quote in a new tab)

Categories of BCG failure: EAU definitions

“Several categories of BCG failures, broadly defined as any HG disease occurring during or after BCG therapy, have been proposed (see Table 7.2).” (opens the source at this quote in a new tab)

“To be able to specify the subgroup of patients where additional BCG is unlikely to provide benefit, the category of BCG-unresponsive tumour was defined. Further BCG instillations in these patients are associated with an increased risk of progression” (opens the source at this quote in a new tab)

“The category of BCG-unresponsive tumours comprises BCG-refractory and early BCG-relapsing tumours (see Table 7.2)” (opens the source at this quote in a new tab)

“BCG-unresponsive tumours include all BCG refractory tumours and those who develop T1/Ta HG recurrence within six months of completion of adequate BCG exposure” (opens the source at this quote in a new tab)

“or develop CIS within 12 months of completion of adequate BCG exposure” (opens the source at this quote in a new tab)

“Adequate BCG is defined as the completion of at least five of six doses of an initial induction course plus at least two out of six doses of a second induction course or two out of three doses of maintenance therapy.” (opens the source at this quote in a new tab)

“Non-HG recurrence after BCG is not considered as BCG failure.” (opens the source at this quote in a new tab)

Epidemiology
Incidence of BCG-unresponsive high-risk non-muscle-invasive bladder cancer
Prevalence of BCG-unresponsive high-risk non-muscle-invasive bladder cancer
Natural history, survival, and mortality
Stage at diagnosis and five-year relative survival by stage, SEER 21, 2016 to 2022
Stage at diagnosisPercent of cases5-year relative survival
In situ“50%”“98.0%”
Localized“34%”“73.0%”
Regional“7%”“41.8%”
Distant“6%”“9.6%”
Unknown“3%”“50.8%”
Pathophysiology
Diagnosis
Clinical presentation - signs and symptoms
Long-term morbidity
Burden of BCG-unresponsive high-risk non-muscle-invasive bladder cancer
Humanistic burden and health-related quality of life
Radical cystectomy versus bladder-sparing therapy: 12-month patient-reported outcomes in recurrent high-grade NMIBC after BCG

“Eligible adults were candidates for both RC or BST, had previous induction Bacillus Calmette-Guérin (BCG), and received their last treatment within 12 months. The primary outcome was the EORTC-QLQ-C30 physical function scale at 12 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Of 570 participants (mean age 71.4 years; 21% female), 371 selected BST and 199 selected RC. Physical function was significantly worse in the RC arm at 3 months; by 9 months, there was no difference between arms, and at 12 months, physical function did not differ (ATE, 0.9; 95% CI, –0.6 to 2.4; P = .22). RC was associated with better emotional function, generic health-related QOL, and financial burden, and lower depression and anxiety, while BST was associated with better bowel and sexual health.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“At 12 months, the primary outcome of EORTC QLQ-C30 physical function did not differ between the BST arm and the RC arm (mean 85.4 [SD, 17.7] v 86.2 [17.6], respectively; ATE, 0.9 [95% CI, –0.6 to 2.4]; P = .22; Fig 2, Data Supplement, Table S10).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Emotional function, cognitive function, global health, anxiety, and depression were significantly better in the RC arm 12 months after enrollment (Fig 2). There were no significant differences between treatment arms in role function and social function.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Participants in the RC arm had significantly worse 12-month bowel and sexual summary scores than those in the BST arm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“EORTC QLQ-C30 physical and role function were significantly worse in the RC arm at 3 months compared with the BST arm, but no significant treatment effects were observed by 9 months, including for physical function among participants age 75 years and older. Emotional function and anxiety were better in the RC arm at all follow-up time points. Urinary and bowel health were significantly worse in the RC arm at 3 months. By 12 months, there were no significant differences between the two treatments with respect to urinary health, but bowel health remained worse in the RC arm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Utility values used in a U.S. cost-effectiveness model of BCG-unresponsive carcinoma in situ
Health stateUtility valueRangeToll
Bladder cancer“0.95”View highlighted excerpt for this quote“0.93–0.97”View highlighted excerpt for this quote“Lifetime”View highlighted excerpt for this quote
Radical cystectomy with ileal conduit“0.8”View highlighted excerpt for this quote“0.7–0.9”View highlighted excerpt for this quote“3 months”View highlighted excerpt for this quote
Neoadjuvant chemotherapy, radical cystectomy, and ileal conduit“0.694”View highlighted excerpt for this quote“0.6–0.9”View highlighted excerpt for this quote“3 months”View highlighted excerpt for this quote
Post-cystectomy state“0.9”View highlighted excerpt for this quote“0.8–0.95”View highlighted excerpt for this quote“Lifetime”View highlighted excerpt for this quote
Metastatic disease“0.62”View highlighted excerpt for this quote“0.5–0.7”View highlighted excerpt for this quote“Lifetime”View highlighted excerpt for this quote
Recurrence“0.8”View highlighted excerpt for this quote“0.75–0.95”View highlighted excerpt for this quote“3 months”View highlighted excerpt for this quote
Disutility: acute minor toxicity (urinary tract infection)“−0.15”View highlighted excerpt for this quote“0–0.3”View highlighted excerpt for this quote“2 weeks”View highlighted excerpt for this quote
Disutility: acute major toxicity (hospitalization)“−0.2”View highlighted excerpt for this quote“0–0.3”View highlighted excerpt for this quote“1 month”View highlighted excerpt for this quote
Disutility: recurrence (TURBT, restaging)“−0.15”View highlighted excerpt for this quote“0–0.3”View highlighted excerpt for this quote“1 month”View highlighted excerpt for this quote
Disutility: radical cystectomy, major complications“−0.07”View highlighted excerpt for this quote“0–0.1”View highlighted excerpt for this quote“1 month”View highlighted excerpt for this quote
Disutility: radical cystectomy, minor complications“−0.03”View highlighted excerpt for this quote“0–0.1”View highlighted excerpt for this quote“1 month”View highlighted excerpt for this quote
Disutility: metastasis, initial“−0.28”View highlighted excerpt for this quote“0.1–0.4”View highlighted excerpt for this quote“1.5 month”View highlighted excerpt for this quote
Economic burden and healthcare resource utilization
Healthcare resource utilization and costs after BCG in high-grade NMIBC, by progression status

“Patients aged ≥ 65 years diagnosed with HG-NMIBC between 2008 and 2015 who received adequate BCG induction and were identified in the SEER-Medicare database.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Of 986 patients diagnosed with HG-NMIBC who met the inclusion criteria, 257 (26.1%) progressed; the mean ages were similar between patients who did and did not progress (77.6 vs. 77.0 years). The overall population had a mean of 0.96 [standard deviation (SD): 1.18] inpatient admissions, 6.47 (11.40) hospitalization days, 1.38 (2.19) emergency department (ED) visits, and 48.03 (44.97) outpatient visits per patient-year during the study period; total annualized costs per patient post-BCG were $39,102 ($44,244).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Patients experiencing progression had significantly higher mean numbers of inpatient admissions [1.61 (SD 1.40) vs. 0.72 (0.99)], hospitalization days [11.77 (14.96) vs. 4.59 (9.29)], ED visits [2.34 (2.92) vs. 1.03 (1.76)], and outpatient visits [65.97 (44.72) vs. 41.63 (43.09)] per patient-year compared with patients without progression (all p < 0.05). Total mean annualized costs per patient after BCG among those who progressed [$65,668 (SD $53,943)] were more than double compared with patients who did not [$29,780 ($36,425)].” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Medicare costs of bladder cancer care by phase of care
Phase of careAnnualized cancer-attributable medical services cost, bladder cancer (2019 US thousand dollars)
Initial (first 12 months after diagnosis)“$25.4”View highlighted excerpt for this quote
Continuing“$6.1”View highlighted excerpt for this quote
End of life, cancer death“$92.2”View highlighted excerpt for this quote
End of life, non-cancer death“$21.8”View highlighted excerpt for this quote
Economic impact of BCG-unresponsive high-risk non-muscle-invasive bladder cancer on families
Financial toxicity after radical cystectomy versus bladder-sparing therapy

“Financial toxicity was measured with the Comprehensive Score for Financial Toxicity (COST),” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“which includes questions about concern with covering the costs of treatment, out-of-pocket expenses, ability to work, and impact and worry about finances. COST scores range from 0 to 44, with lower scores indicating greater financial distress.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Participants in the BST arm reported significantly higher financial toxicity and financial difficulties 12 months after enrollment than participants in the RC arm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Participants in the BST and RC arms endorsed similar financial burden at enrollment. However, by 12 months, participants in the RC arm experienced lower financial difficulties and lower financial toxicity. Although RC is a morbid surgery with a high initial burden, after recovery, those patients mostly experience low health care utilization. Conversely, patients undergoing BST have several induction and maintenance treatments in the year after their recurrence coupled with quarterly surveillance cystoscopies. The financial burden of BST may increase going forward, given recent US Food and Drug Administration approvals of nadofaragene and nogapendekin for BCG-unresponsive NMIBC, which are substantially more expensive than currently available BSTs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Economic impact of diagnostic testing
Medicare cost of surveillance testing during bladder-sparing therapy and after radical cystectomy

Approaches to treatment

Current treatment options and standard of care
Radical cystectomy
Guideline recommendation: radical cystectomy as the standard option for BCG-unresponsive disease

“Patients with BCG-unresponsive disease are unlikely to respond to further BCG therapy; RC is therefore the standard and preferred option.” (opens the source at this quote in a new tab)

“Offer an RC to patients with BCG-unresponsive tumours.” (opens the source at this quote in a new tab)

“Early RC is recommended in patients with BCG-unresponsive tumours and should be considered in BCG-relapsing HG tumours, as discussed in Section 7.8 and Table 7.5.” (opens the source at this quote in a new tab)

“A delay in RC may lead to decreased disease-specific survival” (opens the source at this quote in a new tab)

“Treatments other than RC must be considered oncologically inferior in patients with BCG-unresponsive tumours.” (opens the source at this quote in a new tab)

“However, the potential benefit of RC must be weighed against its risks, morbidity, and impact on quality of life (QoL) and discussed with patients in a shared decision-making process.” (opens the source at this quote in a new tab)

“Offer patients with BCG-unresponsive tumours, who are not candidates for RC due to comorbidities, or who decline RC, preservation strategies (intravesical chemotherapy, chemotherapy and microwave-induced hyperthermia, electromotive administration of chemotherapy, intravesical- or systemic immunotherapy; preferably within clinical trials).” (opens the source at this quote in a new tab)

Standard of care, morbidity, and deferral of surgery
Upfront radical cystectomy compared with bladder-sparing therapy: multicenter retrospective cohort

“Among 578 patients, 28% underwent upfront RC and 72% received BST. The median (interquartile range) follow‐up was 50 (20–69) months. There were no statistically significant differences in metastasis‐free survival, cancer‐specific survival, or overall survival between treatment groups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“RC was performed in 31.7% in the BST group and nodal disease was found in 13% compared with 4% in upfront RC (P = 0.030).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“There were no significant differences in MFS (HR 0.88, 95% CI 0.53–1.46; P = 0.62), CSS (HR 0.91, 95% CI 0.54–1.53; P = 0.73), or OS (HR 1.31, 95% CI 0.91–1.90; P = 0.15) between patients who received upfront RC compared to those receiving BST at time of diagnosis of BCG‐unresponsive NMIBC (Fig. 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Although adverse oncological outcomes began to rise 12 months after diagnosis, the rate of dying from bladder cancer were similar at 14% in both the upfront RC and BST groups at 5 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The low rates of metastasis and death for patients who underwent BST are reassuring, but comparison with RC is impacted by selection bias.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Timing of radical cystectomy after BCG failure
Intravesical chemotherapy
Guideline description: intravesical chemotherapy and chemotherapy combinations

“Valrubicin, an anthracycline topoisomerase inhibitor that interferes with deoxyribonucleic acid (DNA) synthesis and metabolism by inhibiting the activity of DNA topoisomerase II, leading to cell cycle arrest in the G2 phase, was approved by the FDA in 1998, but its use has been limited due to the availability of more effective options” (opens the source at this quote in a new tab)

“have been assessed in a small series of BCG-recurrent NMIBC patients usually not fulfilling the definition of BCG-unresponsive, with inconsistent results.” (opens the source at this quote in a new tab)

“sequential intravesical administration of gemcitabine and docetaxel is an emerging treatment option in patients failing BCG.” (opens the source at this quote in a new tab)

“In a retrospective series of 102 patients with BCG-unresponsive NMIBC, with or without CIS, 6-, 12-, and 24-month HG RFS was 78%, 65% and 49%, respectively.” (opens the source at this quote in a new tab)

“Fifty-seven percent of patients experienced mild/moderate adverse effects, the most common being represented by urinary frequency/urgency (41%) and dysuria (21%) and leading to treatment delay in only 7% of cases” (opens the source at this quote in a new tab)

“Notably, published data on this combination are currently predominantly retrospective, with only one small prospective series reported in Table 7.4” (opens the source at this quote in a new tab)

Gemcitabine alone compared with sequential gemcitabine and docetaxel: regimens and outcomes

“Patients received 2 g of gemcitabine in 100 mL of saline, instilled into the bladder via a catheter for a minimum of 60 minutes once weekly for 6 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Patients received 1 g of gemcitabine in 50 mL of saline, instilled via catheter for 60 to 90 minutes. The bladder was then drained, and 37.5 mg of docetaxel in 50 mL of saline was instilled via a catheter for 60 to 120 minutes. This treatment sequence was administered weekly for 6 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Median HGRFS was similar between groups (gemcitabine: 22.6 months; Gem/Doce: 19.5 months [P=.25]). Among patients with BCG-unresponsive carcinoma in situ (n=49), median HGRFS was comparable (gemcitabine: 12.2 months; Gem/Doce: 7.6 months [P=.12]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Low-grade adverse events were common (gemcitabine: 63%; Gem/Doce: 55% [P=.19]), but grade ≥3 adverse events were rare (2.3% vs 2.4%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Sequential Gem/Doce also poses logistical barriers, including extended chair time, sequential instillation, staffing demands, and reimbursement issues, which may limit its adoption, especially in community settings.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Intravesical gene therapy
Detalimogene voraplasmid: investigational non-viral gene therapy, LEGEND pivotal Cohort 1

“Detalimogene is a novel, investigational, non-viral gene therapy for patients with high-risk, non-muscle invasive bladder cancer (NMIBC), including Bacillus Calmette-Guérin (BCG)-unresponsive disease.” (opens the source at this quote in a new tab)

“The following efficacy data are based on 120 efficacy-evaluable patients enrolled in Cohort 1 as of the data cutoff date, October 29, 2026.” (opens the source at this quote in a new tab)

“CR at any time of 56% (CI:47%, 65%) (n=120)” (opens the source at this quote in a new tab)

“Landmark 12-month CR rate is 24% (CI: 16%, 33%) (n=110)” (opens the source at this quote in a new tab)

“Median duration of complete response is 10.1 months (CI: 7.5, Not Estimable)” (opens the source at this quote in a new tab)

“Of the 125 patients assessed for safety in Cohort 1, 59% experienced at least one TRAE, which were mainly Grade 1/2 in severity.” (opens the source at this quote in a new tab)

“Only 4% of patients experienced Grade 3 TRAE, with just 2% of patients experiencing a serious TRAE. No Grade 4 or Grade 5 TRAEs were reported.” (opens the source at this quote in a new tab)

“The Company expects to initiate the submission by year-end 2026 and plans to complete the BLA submission in the first half of 2027, with potential FDA approval in 2027.” (opens the source at this quote in a new tab)

Interleukin-15 receptor agonists
QUILT-3.032 Cohort A: efficacy in the prescribing information
EndpointNogapendekin alfa inbakicept-pmln with TICE BCG
Participants“n=77”
Complete response rate (95% CI)“62% (51, 73)”
Duration of response, range in months“0.0, 47.0+”
Duration of response ≥12 months, % (n)“58% (28)”
Duration of response ≥24 months, % (n)“40% (19)”
Basis of duration of response“Based on 48 patients that achieved a complete response at any time”
Intravesical drug-releasing systems
SunRISe-1 Cohort 2: efficacy in the prescribing information
EndpointGemcitabine intravesical system
Participants“N=83”
Complete response rate (95% CI)“82% (72, 90)”
Duration of response, range in months“0+, 44+”
Duration of response ≥12 months, % (n)“51% (35)”
Basis of duration of response“Based on patients (n=68) with a complete response at any time”
Immune checkpoint inhibitors
KEYNOTE-057 Cohort A: efficacy in the prescribing information
EndpointPembrolizumab 200 mg every 3 weeks
Participants“n=96”
Complete response rate (95% CI)“41% (31, 51)”
Median duration of response, months (range)“16.2 (0.0+, 30.4+)”
Duration of response ≥12 months, % (n)“46% (18)”
Basis of duration of response“Based on patients (n=39) that achieved a complete response”
KEYNOTE-057 Cohort A: primary publication

“In cohort A of the trial, adults aged 18 years or older with histologically confirmed BCG-unresponsive carcinoma in situ of the bladder, with or without papillary tumours, with an Eastern Cooperative Oncology Group performance status of 0-2, and who were ineligible for or declined radical cystectomy were enrolled.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The primary endpoint was clinical complete response rate (absence of high-risk non-muscle-invasive bladder cancer or progressive disease), assessed by cystoscopy and urine cytology approximately 3 months after the first dose of study drug.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Median follow-up was 36·4 months (IQR 32·0-40·7).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“39 (41%; 95% CI 30·7-51·1) of 96 patients with BCG-unresponsive carcinoma in situ of the bladder with or without papillary tumours had a complete response at 3 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Grade 3 or 4 treatment-related adverse events occurred in 13 (13%) patients; the most common were arthralgia (in two [2%] patients) and hyponatraemia (in three [3%] patients).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

KEYNOTE-057 Cohort B: papillary-only disease
Limitations of current therapies
Summary: limitations of cystectomy and of approved bladder-sparing therapies

The EAU guideline states that radical cystectomy is the standard and preferred option for BCG-unresponsive disease and that other treatments must be considered oncologically inferior; it recommends bladder-preserving strategies, preferably within clinical trials, for patients who are not candidates for cystectomy or who decline it. Up to 80% of patients decline or are ineligible for cystectomy. Reported risks of the procedure include morbidity of 50% to 70% and 90-day mortality of approximately 5% (up to 15% in elderly patients), and a manufacturer-funded cost model states that up to one-quarter of patients die and approximately 70% to 80% experience complications within the first year after surgery.

Pembrolizumab, nogapendekin alfa inbakicept-pmln with BCG, and the gemcitabine intravesical system were each approved on the basis of single-arm trials. Their labeled complete response rates were 41% (96 participants), 62% (77 participants), and 82% (83 participants), and no randomized trial compares these agents with each other or with cystectomy. FDA draft guidance states that a randomized controlled trial is preferable and can provide stronger evidence of effectiveness, that time-to-event endpoints are uninterpretable in a single-arm trial, and that a single-arm study cannot assess the contribution of each drug in a combination. For papillary-only disease resected at or before trial entry, the FDA recommends a randomized controlled trial with a time-to-event endpoint. In October 2026, the FDA extended the nogapendekin alfa inbakicept-pmln indication to papillary-only disease by extrapolation from efficacy in disease containing CIS. Labeling for pembrolizumab and the gemcitabine intravesical system is limited to disease with CIS, and pembrolizumab is further limited to patients ineligible for or electing not to undergo cystectomy. Of 31 BCG-unresponsive trials registered on ClinicalTrials.gov, 15 (48%) had enrollment criteria fully consistent with the FDA definition, which the authors state hinders comparisons across agents.

In a meta-analysis of bladder-sparing trials after BCG failure cited by the EAU guideline, pooled 12-month response rates were 24% for trials with more than 2 prior BCG courses and 36% for those with more than 1, and initial response did not predict durable response. Among responders, 46% (pembrolizumab), 58% (nogapendekin alfa inbakicept-pmln with BCG), and 51% (gemcitabine intravesical system) had a duration of response of at least 12 months in the labels. In QUILT-3.032 Cohort A, complete response rates at the 12-, 24-, and 36-month assessments were 47%, 30%, and 16% of 100 participants; in SunRISe-1 Cohort 2, the complete response rate 12 months after treatment initiation was 45.9%. The QUILT-3.032 median duration of response was considered an unreliable estimate because of the limited sample size, small number of events, and substantial censoring. Progression to muscle-invasive disease occurred in 10% (8 participants) in QUILT-3.032 and 8% (7 of 83 evaluable participants) in SunRISe-1 Cohort 2, and each label warns that delaying cystectomy can lead to muscle-invasive or metastatic disease.

Nogapendekin alfa inbakicept-pmln is given with BCG, and TICE BCG is the only approved BCG strain marketed in the U.S. Merck, its sole U.S. manufacturer since 2012, allocates supply to wholesalers and distributors by historical purchasing patterns; in its 2026 letter to health care professionals it reported delays to full startup of a new facility and stated that it will provide an update on timing in the first quarter of 2027. In Medicare claims, BCG use for initial induction therapy decreased from 38.9% before the shortage to 33.0% during it.

Cystectomy refusal, ineligibility, and perioperative risk
Single-arm trial evidence and FDA trial design recommendations
Durability of complete response
BCG supply constraints
Place in treatment, anticipated use, and care setting
Summary: anticipated place in treatment and care setting

Radical cystectomy is the guideline standard for BCG-unresponsive disease; the EAU 2026 guideline recommends offering it and recommends bladder preservation strategies, preferably within clinical trials, for patients who are not candidates for cystectomy or who decline it. BOND-003 enrolled participants who were medically unfit for cystectomy or who refused it, and the FDA draft guidance states that patients with BCG-unresponsive NMIBC “are unlikely to benefit from further therapy with BCG”. CG Oncology states that only approximately 6% of patients with NMIBC elect cystectomy, and another publication reports real-world rates of radical cystectomy for NMIBC below 20%.

The anticipated first use is in BCG-unresponsive high-risk NMIBC with carcinoma in situ, with or without papillary tumors. In its PIVOT-006 topline release, CG Oncology stated that, based on FDA feedback, the initial BLA will be broadened to include both carcinoma in situ and high-grade papillary-only disease, with completion anticipated in March 2027. Cretostimogene would enter a setting in which the FDA has approved pembrolizumab, nadofaragene firadenovec, nogapendekin alfa inbakicept-pmln with BCG, and TAR-200 for high-risk, BCG-unresponsive NMIBC with CIS ± Ta/T1.

The expected care setting is the urology office. BOND-003 Cohort C was run at 41 community and academic centres. Cretostimogene is instilled through a soft catheter without anesthesia or operating room time, and the company states that a medical assistant or nurse can prepare and administer it. The product is handled under biosafety level 2 precautions, described as “BSL-2 like BCG”, with protective equipment during preparation and administration. CG Oncology describes a field organization directed at community and academic urology networks.

Heterogeneity of treatment effect
BOND-003 Cohort C: tumor pattern and prior therapy at study entry
Baseline characteristicn%
CIS with high-grade Ta/T1“22”“19.6”
CIS alone“90”“80.4”
At least one prior therapy other than BCG“53”“47.3”
Serial adjuvant chemotherapy“34”“30.4”
Systemic immunotherapy“7”“6.3”
Care management intervention strategies
Other product development or post-marketing obligations required by the FDA

Not applicable.

Ongoing post-approval monitoring

Not applicable.

Expected outcomes of therapy